[Correspondence] Efficacy of infliximab biosimilars in patients with Crohn's disease

The NOR-SWITCH study by Kirsten K J ørgensen and coworkers1 (May 11, p 2304) was a double-blind, non-inferiority trial in which patients on originator infliximab therapy were randomly assigned to continue infliximab therapy or to switch to CT-P13, an infliximab biosimilar that has a decreased affinity for FcγRIII receptors.2 The pre specified margin of non-inferiority was 15%. In patients with Crohn's disease, the non-inferiority margin was 15·3%, which was above the pre-specified non-inferiority margin.
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research